Craig E. Devoe, MD, MS | Northwell Health

Dr. Craig E. Devoe

Claim this profile

Northwell Health/Center for Advanced Medicine

Studies Rectal Cancer
Studies Colon Cancer
7 reported clinical trials
17 drugs studied

Area of expertise

1Rectal Cancer
Craig E. Devoe has run 3 trials for Rectal Cancer. Some of their research focus areas include:
ctDNA positive
NRAS positive
KRAS positive
2Colon Cancer
Craig E. Devoe has run 3 trials for Colon Cancer. Some of their research focus areas include:
ctDNA positive
NRAS positive
KRAS positive

Affiliated Hospitals

Image of trial facility.
Northwell Health/Center For Advanced Medicine
Image of trial facility.
Northwell Health

Clinical Trials Craig E. Devoe is currently running

Image of trial facility.

Chemotherapy Tailored by ctDNA Status

for Colon Cancer

This trial tests if a blood test for cancer DNA can help decide if colon cancer patients need more treatment after surgery. The test looks for cancer DNA in the blood to predict if the cancer might come back and to guide further treatment.
Recruiting1 award Phase 2 & 3
Image of trial facility.

Cabozantinib + Nivolumab

for Advanced Skin and Head & Neck Cancers

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine how quickly patients can be divided into groups based on biomarkers in their tumors. A biomarker is a biological molecule found in the blood, other body fluids, or in tissues that is a sign of a normal or abnormal process or a sign of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. The two biomarkers that this trial is studying are "tumor mutational burden" and "tumor inflammation signature." Another purpose of this trial is to help doctors learn if cabozantinib and nivolumab shrink or stabilize the cancer, and whether patients respond differently to the combination depending on the status of the biomarkers.
Recruiting1 award Phase 2

More about Craig E. Devoe

Clinical Trial Related6 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Craig E. Devoe has experience with
  • Irinotecan
  • ELI-002
  • ELI-002 7P
  • Bevacizumab
  • Cholecalciferol
  • Fluorouracil

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Craig E. Devoe specialize in?
Is Craig E. Devoe currently recruiting for clinical trials?
Are there any treatments that Craig E. Devoe has studied deeply?
What is the best way to schedule an appointment with Craig E. Devoe?
What is the office address of Craig E. Devoe?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security